Scientists Crack How a Key Nerve Destruction Protein Switches On
A two-step molecular mechanism explains how SARM1 triggers axon self-destruction — and why some drugs accidentally make it worse.
Summary
SARM1 is a protein that destroys axons by depleting NAD⁺, a molecule critical for cellular energy and longevity. Normally kept inactive, it switches on after nerve injury — but exactly how has been a mystery. Researchers at Tsinghua University used pyridine compounds to reveal a two-step activation process: first, a metabolite called NMN primes SARM1 to generate molecular glue-like compounds; second, these glues drive SARM1 to form spiral filaments that phase-separate into dense, fully active assemblies. Crucially, some existing SARM1-inhibitor drugs inadvertently trigger this same activation pathway. The findings explain how SARM1 activation is spatially confined to damaged axons and open new directions for treating neurodegenerative diseases.
Detailed Summary
Axonal degeneration underlies many neurodegenerative diseases, including ALS, peripheral neuropathy, and traumatic brain injury. SARM1, an enzyme that depletes NAD⁺ through its NADase activity, is a central executioner of this process. Understanding how SARM1 is activated — and how to stop it — is a major goal of longevity-relevant neuroscience.
Researchers used a class of pyridine-containing compounds known to trigger SARM1-dependent axon degeneration as molecular probes to dissect the activation mechanism. They uncovered a sequential, two-step process rather than a simple on/off switch.
In the first step, NMN (nicotinamide mononucleotide — itself a popular longevity supplement) primes SARM1's base exchange activity. This generates covalent adducts between ADP-ribose, a product of NAD⁺ hydrolysis, and the pyridine compounds. In the second step, these ADP-ribose conjugates act as molecular glues, promoting the assembly of superhelical SARM1 filaments in which the TIR catalytic domains adopt an active configuration. Once filament concentration exceeds solubility limits, they condense into phase-separated assemblies — stable, droplet-like structures — with full enzymatic activity.
A striking and clinically important finding is that several SARM1 inhibitors currently in clinical development, which target the TIR domain, also form these ADP-ribose adducts — paradoxically activating rather than inhibiting SARM1 under certain conditions. This is a significant drug development warning.
The phase-separation mechanism elegantly explains how SARM1 activation is spatially restricted to injured axons rather than spreading to healthy tissue. Limitations include reliance on a specific class of chemical probes and the absence of full in vivo validation, meaning the precise dynamics in living nervous systems require further study.
Key Findings
- SARM1 activates via a two-step process: NMN priming followed by ADP-ribose adduct-driven filament assembly.
- SARM1 filaments phase-separate into stable condensates with full NADase activity, spatially restricting activation to damaged axons.
- NMN, a widely used NAD⁺ precursor supplement, plays a direct role in priming SARM1 activation.
- Several clinical-stage SARM1 inhibitor drugs paradoxically promote SARM1 activation by forming the same adducts.
- Phase separation confines SARM1 activity to injured axons, preventing spread to healthy nerve tissue.
Methodology
Researchers employed pyridine-containing chemical probes to dissect SARM1 activation biochemically and structurally. The study characterized covalent adduct formation, superhelical filament assembly, and phase-separated condensates using molecular and structural biology approaches. No full in vivo animal model results are described in the abstract.
Study Limitations
The study relies heavily on a specific class of pyridine compounds as probes, which may not fully represent all physiological activation scenarios. In vivo validation in animal models of nerve injury is not described in the available abstract. The paradoxical activation of clinical inhibitors needs confirmation in cellular and in vivo systems before clinical implications are finalized.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: